S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Closing prices for crude oil, gold and other commodities
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
MarketBeat Week in Review – 1/30 - 2/3
Ford, Starbucks fall; Clorox, Gilead Sciences rise
A gold storm is coming… (Ad)
Skull found in '97 in remote Alaska belongs to New York man
How major US stock indexes fared Friday 2/3/2023
A gold storm is coming… (Ad)
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Treasury makes more electric SUVs eligible for tax credits
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Closing prices for crude oil, gold and other commodities
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
MarketBeat Week in Review – 1/30 - 2/3
Ford, Starbucks fall; Clorox, Gilead Sciences rise
A gold storm is coming… (Ad)
Skull found in '97 in remote Alaska belongs to New York man
How major US stock indexes fared Friday 2/3/2023
A gold storm is coming… (Ad)
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Treasury makes more electric SUVs eligible for tax credits
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Closing prices for crude oil, gold and other commodities
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
MarketBeat Week in Review – 1/30 - 2/3
Ford, Starbucks fall; Clorox, Gilead Sciences rise
A gold storm is coming… (Ad)
Skull found in '97 in remote Alaska belongs to New York man
How major US stock indexes fared Friday 2/3/2023
A gold storm is coming… (Ad)
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Treasury makes more electric SUVs eligible for tax credits
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Closing prices for crude oil, gold and other commodities
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
MarketBeat Week in Review – 1/30 - 2/3
Ford, Starbucks fall; Clorox, Gilead Sciences rise
A gold storm is coming… (Ad)
Skull found in '97 in remote Alaska belongs to New York man
How major US stock indexes fared Friday 2/3/2023
A gold storm is coming… (Ad)
Jury: Musk didn't defraud investors with 2018 Tesla tweets
Treasury makes more electric SUVs eligible for tax credits
NASDAQ:BLFS

BioLife Solutions - BLFS Stock Forecast, Price & News

$26.07
+0.80 (+3.17%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$24.53
$26.62
50-Day Range
$16.95
$26.07
52-Week Range
$10.40
$29.92
Volume
447,337 shs
Average Volume
334,885 shs
Market Capitalization
$1.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.20

BioLife Solutions MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
19.7% Upside
$31.20 Price Target
Short Interest
Healthy
5.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.10mentions of BioLife Solutions in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2.72 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.63) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

598th out of 1,028 stocks

Electromedical Equipment Industry

14th out of 24 stocks

BLFS stock logo

About BioLife Solutions (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.

Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
BioLife Solutions
Should You Invest in BioLife Solutions (BLFS)?
BioLife Solutions Expands Intellectual Property Estate
Earnings Outlook For BioLife Solutions
BioLife Solutions Inc
See More Headlines
Receive BLFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter.

BLFS Company Calendar

Last Earnings
11/09/2022
Today
2/04/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLFS
Employees
432
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$31.20
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$29.00
Forecasted Upside/Downside
+19.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,640,000.00
Pretax Margin
-72.07%

Debt

Sales & Book Value

Annual Sales
$154.81 million
Book Value
$11.80 per share

Miscellaneous

Free Float
41,355,000
Market Cap
$1.11 billion
Optionable
Not Optionable
Beta
1.86

Key Executives

  • Michael P. RiceMichael P. Rice
    Chairman & Chief Executive Officer
  • Geraint Phillips
    Senior Vice President-Global Operations
  • Troy WichtermanTroy Wichterman
    Chief Financial Officer
  • Aby J. MathewAby J. Mathew
    Chief Scientific Officer & Executive VP
  • Roderick de Greef
    Director













BLFS Stock - Frequently Asked Questions

Should I buy or sell BioLife Solutions stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLFS shares.
View BLFS analyst ratings
or view top-rated stocks.

What is BioLife Solutions' stock price forecast for 2023?

1 equities research analysts have issued 12 month price targets for BioLife Solutions' stock. Their BLFS share price forecasts range from $29.00 to $34.00. On average, they anticipate the company's stock price to reach $31.20 in the next year. This suggests a possible upside of 19.7% from the stock's current price.
View analysts price targets for BLFS
or view top-rated stocks among Wall Street analysts.

How have BLFS shares performed in 2023?

BioLife Solutions' stock was trading at $18.20 at the start of the year. Since then, BLFS stock has increased by 43.2% and is now trading at $26.07.
View the best growth stocks for 2023 here
.

Are investors shorting BioLife Solutions?

BioLife Solutions saw a decline in short interest in January. As of January 15th, there was short interest totaling 2,330,000 shares, a decline of 5.7% from the December 31st total of 2,470,000 shares. Based on an average trading volume of 379,600 shares, the short-interest ratio is currently 6.1 days. Currently, 5.9% of the company's shares are sold short.
View BioLife Solutions' Short Interest
.

When is BioLife Solutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our BLFS earnings forecast
.

How were BioLife Solutions' earnings last quarter?

BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings results on Wednesday, November, 9th. The medical equipment provider reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The medical equipment provider had revenue of $40.75 million for the quarter, compared to analysts' expectations of $41.63 million. BioLife Solutions had a negative trailing twelve-month return on equity of 7.50% and a negative net margin of 67.70%.

What guidance has BioLife Solutions issued on next quarter's earnings?

BioLife Solutions updated its FY 2022 earnings guidance on Saturday, January, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $161.90 million-$161.90 million, compared to the consensus revenue estimate of $160.92 million.

What is Mike Rice's approval rating as BioLife Solutions' CEO?

14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend.

What other stocks do shareholders of BioLife Solutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM).

What is BioLife Solutions' stock symbol?

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

Who are BioLife Solutions' major shareholders?

BioLife Solutions' stock is owned by many different institutional and retail investors. Top institutional shareholders include Stephens Investment Management Group LLC (0.92%), New York State Common Retirement Fund (0.83%), Peregrine Capital Management LLC (0.67%), Stephens Inc. AR (0.34%), Janney Montgomery Scott LLC (0.10%) and Yousif Capital Management LLC (0.05%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger.
View institutional ownership trends
.

How do I buy shares of BioLife Solutions?

Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLife Solutions' stock price today?

One share of BLFS stock can currently be purchased for approximately $26.07.

How much money does BioLife Solutions make?

BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $1.11 billion and generates $154.81 million in revenue each year. The medical equipment provider earns $-7,640,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis.

How many employees does BioLife Solutions have?

The company employs 432 workers across the globe.

How can I contact BioLife Solutions?

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433.

This page (NASDAQ:BLFS) was last updated on 2/4/2023 by MarketBeat.com Staff